ALLMedicine™ Folliculitis Center

Oct 14th, 2022 - Although topical drugs are the mainstay of treatment for patients with mild-to-moderate psoriasis, the developments observed in this field in the last two decades have been limited. The most commonly used drugs are still vitamin D analogues and co...

Oct 8th, 2022 - Trachoma is a public health issue in more than 50 nations worldwide, mainly in Sub-Saharan Africa, where hundreds of millions of people are considered blind. Ethiopia is projected to have 30% of the global active trachoma burden. The frequency of ...

Oct 1st, 2022 - Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a typical type-2 inflammation involving T-helper type-2 cells and impairing quality of life due to nasal obstruction, discharge and reduced sense of smell. Recently, the anti-IL4Rα antibody d...

Sep 29th, 2022 - Lichen planopilaris (LPP) is a scarring alopecia for which no treatment with remarkable effect has been identified. Pioglitazone has been reported as a possible therapeutic option. To compare the efficacy and safety of pioglitazone with clobetasol...

Sep 22nd, 2022 - Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are ...

Sep 22nd, 2022 - Malassezia folliculitis is a common disease of young and middle-aged people. It is an inflammatory disease caused by Malassezia infection. Generally, Topical or systemic use of antifungal drugs are the first choice for treatment but sometimes are ...

May 2nd, 2022 - Ialuxid® Gel is a non-antibiotic treatment in gel indicated for use in a variety of skin conditions, and also in case of infection. Its principal ingredient is Ialuvance™ Complex, a proprietary association of hydrogen peroxide, hyaluronic acid, an...

Apr 6th, 2022 - Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldw...

Dec 14th, 2021 - The first-line drug treatment for mild-moderate AD are currently topical corticosteroids (TCS) with recognized efficacy. However, their prolonged or inappropriate use, can lead to local adverse effects. Side-effects of topical corticosteroids comp...

Sep 9th, 2021 - Background and rationale: EGFR represents the main and more studied signal activation pathway in the development of colorectal carcinoma. KRAS, NRAS, BRAF and PI3KA mutations and ERBB2 and MET amplification are responsible for most of the cases of...

Sep 11th, 2022 - The FDA approved the first-in-class oral tyrosine kinase 2 (TYK2) inhibitor deucravacitinib (Sotyktu) for moderate-to-severe plaque psoriasis, Bristol Myers Squibb announced. The indication limits use to adults who are candidates for systemic ther...

Jun 13th, 2022 - The FDA approved the Janus kinase (JAK) inhibitor baricitinib (Olumiant) as the first systemic treatment for alopecia areata. The approval pertains to adults with severe alopecia areata, which affects more than 300,000 people in the U.S. each year...

May 24th, 2022 - The FDA has approved the first topical novel therapy for psoriasis in 25 years, Roivant Sciences announced. Tapinarof cream 1% (Vtama) received an indication for mild, moderate, and severe plaque psoriasis in adults. The approval carries no restri...

May 19th, 2022 - The Sept. 10, 2019 PBS article accompanying the Frontline documentary "Deadly Water" was topped by a provocative headline: "The EPA Says Flint's Water is Safe — Scientists Aren't So Sure." The PBS story relied on a study of adverse health outcomes...

May 4th, 2022 - SAN DIEGO – Combining topical tyrosinase inhibitors with either a nonablative fractional laser or a fractional picosecond laser was safe and effective for treating postinflammatory hyperpigmentation (PIH) in patients with Fitzpatrick skin phototyp.